What it is
BPC-157 is a research peptide studied for tissue repair, gut work, and injury recovery.
Evidence boundary
Investigational with limited human evidence. Do not present it as an established standard.
Trial evidence
- PMID 42198317 — BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
- PMID 40756949 — Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review.
- PMID 41476424 — Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians.
Preparation and measurement
Reconstitution: 10 mg vial + 2 mL BAC = 5 mg/mL.
Concentration matches.
Reference schedule
| Phase | Dose | Draw / measure | Frequency | Weekly total |
|---|---|---|---|---|
| Weeks 1–2 (titration) | 200 mcg | 4 U (0.04 mL) | Once or twice daily | 1.4–2.8 mg/week |
| Weeks 3–4 | 400 mcg | 8 U (0.08 mL) | Once or twice daily | 2.8–5.6 mg/week |
| Weeks 5–8+ (maintenance) | 600 mcg | 12 U (0.12 mL) | Once or twice daily | 4.2–8.4 mg/week |
Weeks 1–2 (titration)
- Dose
- 200 mcg
- Draw / measure
- 4 U (0.04 mL)
- Frequency
- Once or twice daily
- Weekly total
- 1.4–2.8 mg/week
Weeks 3–4
- Dose
- 400 mcg
- Draw / measure
- 8 U (0.08 mL)
- Frequency
- Once or twice daily
- Weekly total
- 2.8–5.6 mg/week
Weeks 5–8+ (maintenance)
- Dose
- 600 mcg
- Draw / measure
- 12 U (0.12 mL)
- Frequency
- Once or twice daily
- Weekly total
- 4.2–8.4 mg/week
Weekly totals apply only during the active phase.
Titration rules
- Light/preventive (250 mcg twice daily): Maintenance and prevention. Common research dose for non-acute use.
- Standard (500 mcg twice daily): Standard soft-tissue repair protocol. Common dose for active healing.
- Aggressive (750 mcg twice daily): Acute injury phase, short-term (≤4 weeks). Not validated for sustained use.
- Cycle structure: 4-week loading at standard dose for active injury → 4-week maintenance at light dose → 2-week break before re-loading if needed.
- Timing: Morning and evening doses, ~12 hours apart. Pre-workout dosing for performance-related protocols. Local injection near injury when feasible.
Cycle length and breaks
An alternative schedule uses continuous low-dose maintenance for chronic conditions; others cycle 4-on, 4-off.
What to monitor
- Local tolerance
- Nausea or fatigue early in use
Practical rules
- Keep expectations modest.
- Rotate sites.
- Pair any recovery protocol with sleep, protein, and load management.
Related protocols
TB-500 (Thymosin Beta-4) Protocol & DosingGHK-Cu Peptide Protocol & DosingBPC-157 + TB-500 Peptide Stack & DosingCartalax Peptide Protocol & Dosing Supply & lot verification
Availability and batch-linked COA records for BPC-157 Peptide Protocol & Dosing are kept with the current product listing.
View availability & COA → Verification notes